Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral …
YH Chan, TF Chao, SW Chen, HF Lee… - European Heart …, 2023 - academic.oup.com
Abstract Aims The Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients
(ELDERCARE-AF) trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was …
(ELDERCARE-AF) trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was …
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral …
YH Chan, TF Chao, SW Chen, HF Lee… - European Heart …, 2023 - pure.lib.cgu.edu.tw
Aims The Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF)
trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was more effective …
trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was more effective …
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral …
YH Chan, TF Chao, SW Chen… - European heart …, 2023 - pubmed.ncbi.nlm.nih.gov
Aims The Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF)
trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was more effective …
trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was more effective …
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral …
YH Chan, TF Chao, SW Chen, HF Lee… - European Heart …, 2023 - academic.oup.com
Abstract Aims The Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients
(ELDERCARE-AF) trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was …
(ELDERCARE-AF) trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was …
Clinical Outcomes in Elderly Atrial Fibrillation Patients at Increased Bleeding Risk Treated with Very-Low-Dose versus Regular-Dose Non-Vitamin K Antagonist Oral …
YH Chan, TF Chao, SW Chen, HF Lee… - European Heart …, 2023 - europepmc.org
Aims The ELDERCARE-AF trial showed that edoxaban at a very-low-dosage (VLD) of 15
mg/day was more effective than a placebo at preventing stroke/systemic embolism without …
mg/day was more effective than a placebo at preventing stroke/systemic embolism without …
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral …
YH Chan, TF Chao, SW Chen, HF Lee, PR Li… - European heart journal …, 2023 - vbn.aau.dk
AIMS: The Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF)
trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was more effective …
trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was more effective …
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral …
YH Chan, TF Chao, SW Chen, HF Lee… - European Heart …, 2023 - pure.lib.cgu.edu.tw
Aims The Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF)
trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was more effective …
trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was more effective …